Heron Therapeutics (NASDAQ: HRTX)
Heron Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Heron Therapeutics Company Info
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.
News & Analysis
Heron (HRTX) Q2 Acute Care Jumps 56%
These 2 Growth Stocks Might Be Incredibly Undervalued Right Now
These two biopharma stocks could be poised for a major growth spurt.
Why Heron Therapeutics Stock Has Been on Fire This Week
Wall Street is cheering a change in leadership at the company.
Why Shares of Heron Therapeutics Jumped Thursday
The stock has been rising since the company appointed a new CEO.
Why Heron Therapeutics Stock Is Getting Hammered Today
The biotech's Q4 results didn't live up to expectations.
Why Heron Therapeutics Shares Rose Nearly 15% This Week
The company got approval for an expanded use for its post-surgery pain therapy.
Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play?
These once-promising biotech stocks are trading at a fraction of their all-time highs right now.
Under Biden's Budget, These 2 Little-Known Biotechs Could Help End the Opioid Crisis
The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.